Blueprint Medicines Corporation

    Blueprint Medicines Corporation

    NNASDAQ:BPMC
    129.46
    USD
    0.00
    (0.00%)
    2013 Y
    2014 Y
    2015 Y
    2016 Y
    2017 Y
    2018 Y
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    2024 Y
    TTM
    Revenue per Share
    - -
    - -
    0.63
    1.01
    0.57
    1.01
    1.39
    14.55
    3.08
    3.42
    4.12
    8.09
    8.85
    Basic EPS, GAAP
    -1.82
    -3.52
    -3.07
    -2.64
    -3.92
    -5.39
    -7.27
    5.76
    -11.01
    -9.35
    -8.37
    -1.07
    -2.45
    Free Cash Flow per Basic Share
    -1.47
    -2.76
    -2
    -0.98
    -3.58
    -4.28
    -6.11
    7.04
    -9.57
    -8.57
    -7.48
    -3.14
    -2.38
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Book Value per Share
    -3.2
    -6.28
    -7.4
    -7.55
    -9.41
    -13.62
    -19.76
    -11.58
    -21.79
    -30.73
    -38.64
    -38.29
    -37.91
    Tangible Book Value per Share
    -3.17
    -6.07
    7.9
    7.75
    16.51
    9.55
    9.71
    26.96
    16.59
    8.63
    2.16
    4.75
    5.39
    Basic Weighted Avg Shares
    13
    13
    18
    27
    38
    44
    48
    55
    59
    60
    61
    63
    63
    Sales/Revenue/Turnover
    - -
    - -
    11
    28
    21
    45
    67
    794
    180
    204
    249
    509
    562
    Operating Margin (%)
    - -
    - -
    -453.02
    -261.33
    -705.9
    -554.86
    -543.25
    38.89
    -352.17
    -259.06
    -193.29
    -41.67
    -31.01
    Depreciation Expense
    1
    1
    1
    2
    2
    4
    5
    7
    6
    12
    12
    16
    16
    Net Income, GAAP
    -21
    -40
    -53
    -72
    -148
    -237
    -348
    314
    -644
    -558
    -507
    -67
    -156
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    0.34
    - -
    - -
    - -
    - -
    61.4
    Profit Margin (%)
    - -
    - -
    -462.89
    -261.04
    -691.3
    -531.53
    -522.75
    39.54
    -357.67
    -273.24
    -203.3
    -13.19
    -27.7
    Working Capital
    -1
    42
    152
    192
    643
    439
    410
    797
    404
    863
    593
    482
    451
    LT Debt
    2
    7
    7
    4
    15
    13
    89
    82
    103
    215
    290
    412
    409
    Total Equity
    -1
    35
    144
    213
    624
    419
    464
    1,470
    971
    515
    131
    299
    342
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    29.03
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    -45.13
    - -
    - -
    - -
    - -
    -106.97
    Return on Common Equity (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -

    Capital Structure

    USD

    •

    in mil. unless spec.
    Sep'24
    Dec'24
    Mar'25
    ST Debt
    58
    57
    58
    LT Borrowings
    342
    343
    344
    LT Finance Leases
    72
    69
    65
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    63
    64
    65
    Market Capitalization
    5,751
    5,482
    5,619

    Working Capital

    USD

    •

    in mil. unless spec.
    Sep'24
    Dec'24
    Mar'25
    Total Current Assets
    855
    743
    702
    Cash, Cash Equivalents & STI
    734
    615
    576
    Accounts Receivable, Net
    66
    76
    78
    Inventories
    13
    14
    13
    Total Current Liabilities
    258
    261
    251
    Payables & Accruals
    64
    60
    61
    ST Debt
    58
    57
    58
    Deferred Revenue
    64
    64
    70

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    71.49%
    37.94%
    128.67%
    Free Cash Flow
    -8.1%
    -110.77%
    -56.46%
    Net Income, GAAP
    -32.54%
    -120.95%
    -86.77%
    Sales/Revenue/Turnover
    - -
    231.12%
    104.04%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    63
    58
    57
    72
    249
    2024
    96
    138
    128
    146
    509
    2025
    149
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    -2.15
    -2.19
    -2.2
    -1.82
    -8.37
    2024
    1.45
    -0.8
    -0.89
    -0.79
    -1.07
    2025
    0.01
    - -
    - -
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • businesswire.com

      Shareholder Alert: The Ademi Firm Investigates the Blueprint Medicines Corporation Transaction

    • globenewswire.com

      $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Blueprint Medicines Corporation (NASDAQ: BPMC)

    • businesswire.com

      BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC

    • globenewswire.com

      HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Blueprint Medicines Corporation (NASDAQ: BPMC)

    • prnewswire.com

      Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses

    • businesswire.com

      BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC

    • youtube.com

      Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz

    • zacks.com

      Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines

    • globenewswire.com

      Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines

    • businesswire.com

      Shareholder Alert: The Ademi Firm Investigates Whether Blueprint Medicines Corporation Is Obtaining a Fair Price for Its Public Shareholders

    • businesswire.com

      BPMC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Blueprint Medicines Corporation Is Fair to Shareholders

    • barrons.com

      Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal.

    • wsj.com

      Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion

    • globenewswire.com

      Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

    • globenewswire.com

      Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

    • globenewswire.com

      Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

    • businesswire.com

      VantAI Expands Strategic Collaboration with Blueprint Medicines to Advance Induced Proximity Drug Discovery

    • zacks.com

      Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings

    • seekingalpha.com

      Blueprint Medicines Corporation (BPMC) Q1 2025 Earnings Call Transcript

    • zacks.com

      Blueprint Medicines (BPMC) Reports Q1 Loss, Lags Revenue Estimates